Organigram Global Q2 Earnings Call Highlights
Key takeaways
- Organigram Global Q2 Earnings Call Highlights Market Beat Tue, May 12, 2026 at 8:07 PM GMT+7 9 min read OGI Organigram Global logo Key Points Interested in Organigram Global Inc.?
- Organigram Global posted weaker fiscal Q2 2026 results, with net revenue down about 9% year over year to CAD 59.8 million and adjusted EBITDA falling to CAD 0.9 million.
- The company said it is taking corrective action, including tighter quality controls for infused pre-rolls and a product refresh in vapes, where share fell as consumer demand shifted toward higher-potency formats.
Organigram Global Q2 Earnings Call Highlights Market Beat Tue, May 12, 2026 at 8:07 PM GMT+7 9 min read OGI Organigram Global logo Key Points Interested in Organigram Global Inc.? Here are five stocks we like better.
Organigram Global posted weaker fiscal Q2 2026 results, with net revenue down about 9% year over year to CAD 59.8 million and adjusted EBITDA falling to CAD 0.9 million. Management blamed operational issues in vapes and infused pre-rolls, softer Canadian market growth, and international flower spec challenges.
The company said it is taking corrective action, including tighter quality controls for infused pre-rolls and a product refresh in vapes, where share fell as consumer demand shifted toward higher-potency formats. Despite those setbacks, Organigram said flower, edibles, beverages and concentrates showed strength and it remained Canada’s No. 1 licensed producer by market share.